Adverse events in bevacizumab and chemotherapy: patient management.
AffiliationChristie Hospital NHS Foundation Trust, Manchester.
MetadataShow full item record
AbstractBevacizumab (Avastin) is an anti-angiogenic agent recently approved for the treatment of metastatic breast cancer in combination with paclitaxel. It is important that nurses are familiar with the side-effects associated with this agent--several of which differ from those seen with traditional chemotherapy agents--and how these can be optimally identified, monitored and managed. Side-effects associated with bevacizumab include hypertension, proteinuria, thromboembolic events, bleeding, cardiac toxicity, wound-healing complications and gastrointestinal perforations. Many of these are easily manageable, often without the need to discontinue bevacizumab therapy. This article, the second in a series, provides nurses with management recommendations for these toxicities in order to deliver optimal patient care and improve patients quality of life.
CitationAdverse events in bevacizumab and chemotherapy: patient management., 18 (7):424-8 Br J Nurs
JournalBritish Journal of Nursing
- Managing adverse events in the use of bevacizumab and chemotherapy.
- Authors: Blowers E, Hall K
- Issue date: 2009 Mar 26-Apr 8
- Managing patients treated with bevacizumab combination therapy.
- Authors: Gordon MS, Cunningham D
- Issue date: 2005
- Safety of bevacizumab in patients with metastatic breast cancer.
- Authors: Hamilton EP, Blackwell KL
- Issue date: 2011
- Intricacies of bevacizumab-induced toxicities and their management.
- Authors: Gressett SM, Shah SR
- Issue date: 2009 Mar
- Managing patients with metastatic colorectal cancer on bevacizumab.
- Authors: Lemmens L, Claes V, Uzzell M
- Issue date: 2008 Aug 14-Sep 10